Your browser doesn't support javascript.
loading
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
Fajgenbaum, David C; Uldrick, Thomas S; Bagg, Adam; Frank, Dale; Wu, David; Srkalovic, Gordan; Simpson, David; Liu, Amy Y; Menke, David; Chandrakasan, Shanmuganathan; Lechowicz, Mary Jo; Wong, Raymond S M; Pierson, Sheila; Paessler, Michele; Rossi, Jean-François; Ide, Makoto; Ruth, Jason; Croglio, Michael; Suarez, Alexander; Krymskaya, Vera; Chadburn, Amy; Colleoni, Gisele; Nasta, Sunita; Jayanthan, Raj; Nabel, Christopher S; Casper, Corey; Dispenzieri, Angela; Fosså, Alexander; Kelleher, Dermot; Kurzrock, Razelle; Voorhees, Peter; Dogan, Ahmet; Yoshizaki, Kazuyuki; van Rhee, Frits; Oksenhendler, Eric; Jaffe, Elaine S; Elenitoba-Johnson, Kojo S J; Lim, Megan S.
Afiliação
  • Fajgenbaum DC; Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Uldrick TS; National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Bagg A; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Frank D; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Wu D; Department of Laboratory Medicine, University of Washington, Seattle, WA.
  • Srkalovic G; Sparrow Cancer Center, Edward W. Sparrow Hospital Association, Lansing, MI.
  • Simpson D; Division of Haematology, North Shore Hospital, Auckland, New Zealand.
  • Liu AY; Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Menke D; Division of Hematology, Department of Medicine, and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
  • Chandrakasan S; Department of Medicine, Emory University School of Medicine, Atlanta, GA.
  • Lechowicz MJ; Department of Medicine, Emory University School of Medicine, Atlanta, GA.
  • Wong RS; Sir Y.K. Pao Centre for Cancer and Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
  • Pierson S; Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Paessler M; Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Rossi JF; Department of Hematology, Hôpital Saint Éloi University Hospital, Montpellier, France.
  • Ide M; Department of Hematology, Takamatsu Red Cross Hospital, Takamatsu, Kagawa, Japan.
  • Ruth J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Croglio M; School of Medicine, Stony Brook University, Stony Brook, NY.
  • Suarez A; Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Krymskaya V; Division of Pulmonary, Allergy, and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Chadburn A; Department of Pathology, Weill Cornell Medical College, New York, NY.
  • Colleoni G; Departamento de Oncologia Clínica e Experimental, Universidade Federal de São Paulo, São Paulo, Brazil.
  • Nasta S; Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Jayanthan R; Department of Pediatrics, Texas Children's Hospital, Houston, TX.
  • Nabel CS; Department of Medicine, Brigham and Women's Hospital, Boston, MA.
  • Casper C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Dispenzieri A; Division of Hematology/Oncology, Mayo Clinic, Rochester, MN.
  • Fosså A; Department of Oncology, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.
  • Kelleher D; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Kurzrock R; Center for Personalized Therapy and Clinical Trials Office, UC San Diego Moores Cancer Center, La Jolla, CA.
  • Voorhees P; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.
  • Dogan A; Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Yoshizaki K; Department of Organic Fine Chemicals, The Institute of Scientific and Industrial Research, Osaka University, Osaka, Japan.
  • van Rhee F; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR; and.
  • Oksenhendler E; Department of Clinical Immunology, Hôpital Saint-Louis, Paris, France.
  • Jaffe ES; National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Elenitoba-Johnson KS; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Lim MS; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Blood ; 129(12): 1646-1657, 2017 Mar 23.
Article em En | MEDLINE | ID: mdl-28087540
ABSTRACT
Human herpesvirus-8 (HHV-8)-negative, idiopathic multicentric Castleman disease (iMCD) is a rare and life-threatening disorder involving systemic inflammatory symptoms, polyclonal lymphoproliferation, cytopenias, and multiple organ system dysfunction caused by a cytokine storm often including interleukin-6. iMCD accounts for one third to one half of all cases of MCD and can occur in individuals of any age. Accurate diagnosis is challenging, because no standard diagnostic criteria or diagnostic biomarkers currently exist, and there is significant overlap with malignant, autoimmune, and infectious disorders. An international working group comprising 34 pediatric and adult pathology and clinical experts in iMCD and related disorders from 8 countries, including 2 physicians that are also iMCD patients, was convened to establish iMCD diagnostic criteria. The working group reviewed data from 244 cases, met twice, and refined criteria over 15 months (June 2015 to September 2016). The proposed consensus criteria require both Major Criteria (characteristic lymph node histopathology and multicentric lymphadenopathy), at least 2 of 11 Minor Criteria with at least 1 laboratory abnormality, and exclusion of infectious, malignant, and autoimmune disorders that can mimic iMCD. Characteristic histopathologic features may include a constellation of regressed or hyperplastic germinal centers, follicular dendritic cell prominence, hypervascularization, and polytypic plasmacytosis. Laboratory and clinical Minor Criteria include elevated C-reactive protein or erythrocyte sedimentation rate, anemia, thrombocytopenia or thrombocytosis, hypoalbuminemia, renal dysfunction or proteinuria, polyclonal hypergammaglobulinemia, constitutional symptoms, hepatosplenomegaly, effusions or edema, eruptive cherry hemangiomatosis or violaceous papules, and lymphocytic interstitial pneumonitis. iMCD consensus diagnostic criteria will facilitate consistent diagnosis, appropriate treatment, and collaborative research.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperplasia do Linfonodo Gigante / Herpesvirus Humano 8 Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Panamá

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperplasia do Linfonodo Gigante / Herpesvirus Humano 8 Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Panamá